FMP
Harmony Biosciences Holdings, Inc.
HRMY
NASDAQ
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
29.35 USD
-0.05 (-0.17%)
About
ceo
Dr. Jeffrey M. Dayno M.D.
sector
Healthcare
industry
Biotechnology
website
https://www.harmonybiosciences.com
exchange
NASDAQ
Description
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is based in Plymouth Meeting, Pennsylvania.
CIK
0001802665
ISIN
US4131971040
CUSIP
413197104
Address
630 West Germantown Pike
Phone
484 539 9800
Country
US
Employee
246
IPO Date
Aug 19, 2020
Key Executives
